Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.

Abstract: Disclosed are delayed release oral tranexamic acid formulations and methods of treatment therewith.

Abstract: Disclosed are immediate release oral tranexamic acid formulations and methods of treatment therewith.

Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.

Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.

Abstract: Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.

Abstract: Disclosed are oral tranexamic acid formulations and methods of treatment therewith.

Abstract: Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.

Abstract: Disclosed are oral tranexamic acid formulations and methods of treatment therewith.

Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.

Abstract: The present invention relates to stabilized formulations for parenteral administration comprising a therapeutically effective amount of levomepromazine or a pharmaceutically acceptable salt thereof, and selected stabilizers in an amount effective to stabilize said formulation, to stable terminally sterilized levomepromazine formulations, to methods stabilizing pharmaceutical formulations comprising levomepromazine, and to methods of treating disorders using said formulation.

Abstract: A pharmaceutically active N-desmethyl levomepromazine (abbreviated NDM LMP) and method of use. NDM LMP has substantially the same therapeutic effects as the parent levomepromazine but is subject to less disposition (e.g. presystemic and systemic metabolism) and thus has improved properties over the parent.

Abstract: Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.

Abstract: Compositions and methods for parenterally administering methadone. The methadone composition may be administered in a sterile, preservative-free formulation, or in a formulation including a chlorobutanol-free, government approved preservative. The methadone formulations are administered parenterally, such as intravenously or topically, for many applications including the treatment of pain resulting from chronic disorders, cancer, acute symptoms and the like.

Abstract: Compositions and method including a visual marker for monitoring patient compliance with a medication regimen. The marker is formulated with a rapid dissolve layer and adhered to, or ingested with, an orally administrable medicament. Upon ingestion, the marker is released causing a detectable marker-induced property in the oral and/or pharyngeal cavity of a subject. By examining the patient's oral and/or pharyngeal cavity and articles associated with the patient, one can determine whether the medicament has been ingested based upon the presence or absence of the property. The composition is also useful for tracking the location of an un-ingested medicament.

Abstract: Stable, solid formulations of choline salicylate and hydrophilic silicon dioxide, a process for their preparation and a method for their use.